Dianthus Therapeutics Inc. (DNTH)vsRevolution Medicines Inc (RVMD)
DNTH
Dianthus Therapeutics Inc.
$91.57
-4.30%
HEALTHCARE · Cap: $5.01B
RVMD
Revolution Medicines Inc
$182.08
+2.19%
HEALTHCARE · Cap: $36.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Dianthus Therapeutics Inc. generates 80% more annual revenue ($1.34M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
DNTH
Avoid24
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -22.7% — below average capital efficiency
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DNTH
The strongest argument for DNTH centers on Debt/Equity, Altman Z-Score.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : DNTH
The primary concerns for DNTH are EPS Growth, Profit Margin, Piotroski F-Score.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
DNTH is growing revenue faster at -60.2% — sustainability is the question.
DNTH generates stronger free cash flow (-29M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DNTH scores higher overall (24/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Dianthus Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?